IBIO, Inc.

Ticker IBIO

Exchange NYSE More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in New York City, New York

iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, produced using the Company's proprietary gene expression technology, is the first product candidate from this program being advanced for IND development. The Company also offers proprietary products and product…More

Visit website

REPORT RATINGS

4.8 / 5.0 (204)

IBIO, Inc. reports have an aggregate usefulness score of 4.8 based on 204 reviews.

IBIO, Inc.

Most Recent Annual Report

MOST RECENT 2023 Annual Report and Form 10K

View PDF View Form 10K (HTML)

IBIO, Inc. does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.